Drugs / 14Nitrogen Sodium Nitrite
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01681810 | Oct 2012 → Feb 2018 | hypertensive disorder, metabolic syndrome X | Gladwin, Mark, MD | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14Nitrogen Sodium Nitrite | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01681810 ↗ |
| Route | Oral | “oral formulation of sodium nitrite 40 mg three times a day for 12 weeks” NCT01681810 ↗ |